Will a biotech ri­val fi­nal­ly shake up Ab­b­Vie's $2B Botox cos­met­ic fran­chise? Re­vance will find out soon

For 20 years, Botox — short for the neu­ro­tox­ic pro­tein bot­u­linum tox­in — has reigned supreme as the most pop­u­lar cos­met­ic pro­ce­dure. Even as Evo­lus man­aged to score an FDA ap­proval for a ri­val prod­uct named Jeu­veau, its 2021 sales of al­most $100 mil­lion were no match for the $2.2 bil­lion rev­enue Ab­b­Vie re­port­ed for Botox Cos­met­ic alone.

But that could change by the end of this year.

Re­vance, the Nashville, TN-based biotech de­vel­op­ing Dax­i­bot­u­linum­tox­i­nA in­jec­tion for mod­er­ate to se­vere glabel­lar lines — a fan­cy term for frown lines or wrin­kles — said the FDA has ac­cept­ed its BLA re­sub­mis­sion six months af­ter a re­jec­tion, which it had blamed on man­u­fac­tur­ing is­sues. It’s giv­en a PDU­FA date of Sept. 8.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER